References
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin . 2020; 70:7–30.
  2. Lima A, Seabra V, Martins S, Coelho A, Araújo A, & Medeiros R. Thymidylate synthase polymorphisms are associated with the therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Mol. Biol. Rep .2014; 41(5): 3349-3357.
  3. Choi JR, Kim JO, Kang DR, Shin, JY, Zhang XH, Oh JE, Park JY, Kim KA and Kang JH. Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat: official journal of Korean Cancer Association . 2015; 47(3): 509.
  4. Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA and Sparreboom A. Modulation of OATP1Btype transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther.2013; 12(8): 1537-1544.
  5. Lin L, Yee SW, Kim RB, & Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug discov . 2015: 14 (8): 543-560.
  6. Sutherland R, Meeson A, Lowes S. Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis. Cancer and Metastasis Reviews . 2020; 39(3):919-932.
  7. Abdel-Haleem, Alyaa M, et al. Expression of RFC/SLC19A1 is associated with tumor type in bladder cancer patients. PloS one.2011; 6(7): e21820.
  8. Chango A, Emery-Fillon N, De Courcy GP et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70(4): 310–315.
  9. Wang L, Chen W, Wang J, Tan Y, Zhou Y, Ding W, et al. Reduced folate carrier gene G80A polymorphism is associated with an increased risk of gastroesophageal cancers in a Chinese population. Eur J Cancer . 2006; 42:3206–3211.
  10. Lima A, Bernardes M, Sousa H, Azevedo R, Costa L, Ventura F, Medeiros R. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.Pharmacogenomics .2014;15(6): 807-820.
  11. Adjei AA, Salavaggione OE, MandrekarSJ, DyGK, ZieglerKLA, EndoC, AdjeiAA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: A North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol . 2010; 5(9): 1346-1353.
  12. Roth M, Obaidat A, & Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol . 2012; 165(5): 1260–1287.
  13. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C. identification of multiple allelic variants associated with altered transport activity among European and African-Americans. J Biol Chem . 2001;276(38):35669–75.
  14. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics . 2004;14(11):749–57.
  15. ShitaraY,et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles inhepatic clearance and intestinal absorption. Biopharm Drug Dispos .2013;34: 45-78. doi:10.1002/bdd.1823.
  16. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther . 2002;302(2):804–13.
  17. KiyotaniK, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia. Cancer Sci . 2008; 99(5): 967-972.
  18. Yamada A, Maeda K, Kiyotani K, Mushiroda T, Nakamura Y, Sugiyama Y. Kinetic interpretation of the importance of OATP1B3 and MRP2 in docetaxel‐induced hematopoietic toxicity. CPT: pharmacometrics & systems pharmacology . 2014; 3(7): 1-10.
  19. Liu J, Long J, Zhang S, FangX, Luo Y. Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China. Ital JPediatr .2013; 39 (1): 1-5.
  20. Nagy A, Szalai R, Magyari L, Bene J, Toth K,Melegh B. Extreme differences in SLCO1B3 functional polymorphisms in Roma and Hungarian populations.EnvironToxicolPharmacol .2015; 39(3): 1246-1251.
  21. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, Davis M, Lane JA, Donovan J, Smith GD, Neal DE. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol. Biomark. Prev. 2009 ;18(9):2528-2539.
  22. Liu H, Jin G, Wang H, WuW, Liu Y, Qian J, Sun W. Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. Lung Cancer. 2008; 61(1): 21-29.
  23. Lima A, BernardesM, AzevedoR, Monteiro J, SousaH, Medeiros R, Seabra V. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014; 142(1):196-209.
  24. Jabeen S, Holmboe L, Alnæs G IG, Andersen AM, Hall K S, Kristensen VN. Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. The pharmacogenomics journal .2015;15(5): 385-390.
  25. Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol. 2017;83:1176-1184. doi:10.1111/bcp.13207
  26. Sissung TM et al. Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.Discov Med . 2012;13: 19-34 .
  27. Liutkeviciene R, Vilkeviciute A, Slavinskaite A, Petrauskaite A, Tatarunas V, Kriauciuniene L. Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration. Gene . 2018;676:139-45.
  28. Niemi M, Pasanen MK, Neuvonen P. Organic Anion Transporting Polypeptide 1B1: A Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacol. Rev.  2011;63:157–181. doi: 10.1124/pr.110.002857.
  29. Gong IY, Kim RB. Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response. Drug Metab. Pharmacokinet. 2013; 28: 4–18.
  30. Feng W, Liu X, Zhao X, Huang M, Guo W, Yin J, & Zhu X. Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. Oncol Lett . 2018; 16 (4): 4489-4497.
  31. Li Y, Gan S, Ren L, Yuan L, Liu J, Wang W, & Qi, X. Multifaceted regulation and functions of replication factor C family in human cancers. Am. J. Cancer Res. 2018; 8 (8): 1343.
  32. Nunez MI, Behrens C, Woods DM, LinH, Suraokar M, Kadara, H, Wistuba, II. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation. J. Thorac. Oncol . 2012; 7 (5): 833-840.
  33. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M et al . Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood  .1997; 89: 1013–1018.
  34. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer.  2012; 78: 92–9.
  35. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.  2009; 27: 2038–45.
  36. Goricar K, Kovac V, & Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol oncol . 2014; 48 (2): 163.
  37. Chew SC, Sandanaraj E, Singh O, Chen X, Tan EH, Lim WT, & Chowbay B. Influence of SLCO1B3 haplotype‐tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br. J. Clin. Pharmacol . 2012; 73 (4): 606-618.
  38. Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJD, Tan EH, Lim WT, Chowbay B. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer  Chemother. Pharmacol.  2011;67:1471–8
  39. Ieiri I, Higuchi S, & Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.  Expert Opin Drug Metab Toxicol. 2009; 5 (7): 703-729.
  40. Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, & Mathijssen RH. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics . 2016; 17 (14): 1483-1490.
  41. Robien K, Boynton A, & Ulrich CM. Pharmacogenetics of folate-related drug targets in cancer treatment. 2005: 673-689.
  42. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen R H, & Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat . 2011; 14 (1): 22-34.
  43. Ho RH, & Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharm Therap . 2005; 78 (3): 260-277.
  44. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL and Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos.2007; 35(8): 1333-1340.
  45. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D. & Relling M V. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol . 2009; 27 (35): 5972.
  46. Plaza-Plaza JC, Aguilera M, Cañadas-Garre M, Chemello C, González-Utrilla, A, Faus Dader MJ, & Calleja MA. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. Omics: a journal of integrative biology . 2012:16 (11); 589-595.
  47. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, & Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. The pharmacogenomics journal . 2013; 13 (3): 227-234.